A three-year-old boy’s liver cancer has been in complete remission for a year after an experimental CAR-T immunotherapy. Researchers engineered the boy’s own T cells to target a protein called glypican-3 on his hepatoblastoma cells. buff.ly/pzm3veU
#ShareGoodNewsToo
#ShareGoodNewsToo
Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy | NEJM
A 3-year-old boy with chemotherapy-resistant metastatic hepatoblastoma had complete regression lasting at least 12 months after two infusions of glypican-3–specific CAR T cells coexpressing interle...
buff.ly
November 6, 2026 at 1:50 PM
A three-year-old boy’s liver cancer has been in complete remission for a year after an experimental CAR-T immunotherapy. Researchers engineered the boy’s own T cells to target a protein called glypican-3 on his hepatoblastoma cells. buff.ly/pzm3veU
#ShareGoodNewsToo
#ShareGoodNewsToo
In patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation, ziltivekimab decreased interleukin-6 levels but did not result in fewer cardiovascular events than placebo. Full ZEUS trial results: https://nej.md/3UCOqQC
#ScientificSessions26
#ScientificSessions26
November 7, 2026 at 2:42 PM
In patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation, ziltivekimab decreased interleukin-6 levels but did not result in fewer cardiovascular events than placebo. Full ZEUS trial results: https://nej.md/3UCOqQC
#ScientificSessions26
#ScientificSessions26
Efficient production of highly bioactive interleukin-15 in the silkworm silk gland bioreactor
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
November 7, 2026 at 3:11 AM
Efficient production of highly bioactive interleukin-15 in the silkworm silk gland bioreactor
onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com/doi/10.1111/...
Interleukin-1 Alpha Market Competitive Landscape Report 2035 | WiseGuyReports www.wiseguyreports.com/reports/inte...
Interleukin-1 Alpha Market Competitive Landscape Report 2035
Interleukin-1 Alpha Market Is Projected To Reach a Valuation of USD 800 Billion by 2035, Growing at a CAGR of 5.9% During the Forecast Period 2026 - 2035
www.wiseguyreports.com
November 9, 2026 at 11:40 AM
Interleukin-1 Alpha Market Competitive Landscape Report 2035 | WiseGuyReports www.wiseguyreports.com/reports/inte...
Molecular and functional characterization of interleukin-11b in large yellow croaker (Larimichthys crocea) during pathogen-induced immune responses https://pubmed.ncbi.nlm.nih.gov/42998797/
November 9, 2026 at 10:33 AM
Molecular and functional characterization of interleukin-11b in large yellow croaker (Larimichthys crocea) during pathogen-induced immune responses https://pubmed.ncbi.nlm.nih.gov/42998797/
🚨 $HOWL
On November 9, 2026, Werewolf Therapeutics, Inc. issued a press release announcing new clinical data from its Phase 1/1b clinical trial of WTX-124 and its Phase 1b/2 clinical trial of WTX-330, its conditionally activated Interleukin-2 and Interleukin-12 INDUKINE TM molecules, respectively...
On November 9, 2026, Werewolf Therapeutics, Inc. issued a press release announcing new clinical data from its Phase 1/1b clinical trial of WTX-124 and its Phase 1b/2 clinical trial of WTX-330, its conditionally activated Interleukin-2 and Interleukin-12 INDUKINE TM molecules, respectively...
SEC Filing: HOWL
Click to view the official SEC document.
www.sec.gov
November 9, 2026 at 2:23 PM
🚨 $HOWL
On November 9, 2026, Werewolf Therapeutics, Inc. issued a press release announcing new clinical data from its Phase 1/1b clinical trial of WTX-124 and its Phase 1b/2 clinical trial of WTX-330, its conditionally activated Interleukin-2 and Interleukin-12 INDUKINE TM molecules, respectively...
On November 9, 2026, Werewolf Therapeutics, Inc. issued a press release announcing new clinical data from its Phase 1/1b clinical trial of WTX-124 and its Phase 1b/2 clinical trial of WTX-330, its conditionally activated Interleukin-2 and Interleukin-12 INDUKINE TM molecules, respectively...
New experiments in #ScienceSignaling present a rational cytokine-engineering strategy to activate immune signaling networks and provide clues about whether the cytokine IL-39 is found in the human body—a longstanding debate in immunology. https://scim.ag/3V8FhQ9
Subunit engineering enables the generation of human interleukin-39 as a proinflammatory cytokine
Rational design enables human cells to produce an inflammatory cytokine that may not be made naturally.
scim.ag
November 4, 2026 at 4:00 PM
New experiments in #ScienceSignaling present a rational cytokine-engineering strategy to activate immune signaling networks and provide clues about whether the cytokine IL-39 is found in the human body—a longstanding debate in immunology. https://scim.ag/3V8FhQ9
Elisabeth Bik joins the treasure hunt on Fulda & Debatin papers. Report her to police, @uniulm.bsky.social !
And apparently @dfg.de opened a second investigation!
pubpeer.com/publications...
And apparently @dfg.de opened a second investigation!
pubpeer.com/publications...
PubPeer - Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced...
There are comments on PubPeer for publication: Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme...
pubpeer.com
November 5, 2026 at 6:32 AM
Elisabeth Bik joins the treasure hunt on Fulda & Debatin papers. Report her to police, @uniulm.bsky.social !
And apparently @dfg.de opened a second investigation!
pubpeer.com/publications...
And apparently @dfg.de opened a second investigation!
pubpeer.com/publications...
Single-cell transcriptomics reveals the heterogeneous landscape of innate lymphoid cells in zebrafish
Single-cell transcriptomics reveals the heterogeneous landscape of innate lymphoid cells in zebrafish
In this study, Cheng et al. delineate a comprehensive atlas of innate lymphoid cells in zebrafish, unraveling their tissue distribution and developmental origins, and demonstrating interleukin-2 receptor beta as a critical regulator for their immune activity.
dlvr.it
November 9, 2026 at 12:23 AM
Single-cell transcriptomics reveals the heterogeneous landscape of innate lymphoid cells in zebrafish
The authors included RRIDs in their in Advanced Healthcare Materials paper! We value the author's support of reproducibility. #methodsmatter #BetterScience #OpenResearch
Anti-Inflammatory and Neuroactive Effects of Polymer-Coated Iron Oxide Nanoparticles Functionalized With Interleukin 4 for Spinal Cord Injury
Read the full paper: Anti-Inflammatory and Neuroactive Effects of Polymer-Coated Iron Oxide Nanoparticles Functionalized With Interleukin 4 for Spinal Cord Injury
doi.org
November 6, 2026 at 8:00 AM
The authors included RRIDs in their in Advanced Healthcare Materials paper! We value the author's support of reproducibility. #methodsmatter #BetterScience #OpenResearch
🚨🧵by Zdenek Vrozina on XTwitter:
"The strongest immune trace of long COVID in the blood isn't a flare up of inflammation. It's a brake left pressed down. A new study finds the clearest immune signal in LC is raised IL-1RA..."
22-tweet🧵
threadreaderapp.com/thread/21180...
"The strongest immune trace of long COVID in the blood isn't a flare up of inflammation. It's a brake left pressed down. A new study finds the clearest immune signal in LC is raised IL-1RA..."
22-tweet🧵
threadreaderapp.com/thread/21180...
November 5, 2026 at 4:42 AM
🚨🧵by Zdenek Vrozina on XTwitter:
"The strongest immune trace of long COVID in the blood isn't a flare up of inflammation. It's a brake left pressed down. A new study finds the clearest immune signal in LC is raised IL-1RA..."
22-tweet🧵
threadreaderapp.com/thread/21180...
"The strongest immune trace of long COVID in the blood isn't a flare up of inflammation. It's a brake left pressed down. A new study finds the clearest immune signal in LC is raised IL-1RA..."
22-tweet🧵
threadreaderapp.com/thread/21180...
The catalytic residue of the TLR4 TIR is required for immune signaling in human cells.
In our updated preprint with @v-hornung.bsky.social’s lab, we show that a single point mutation in this site abolishes the LPS response in macrophages 🧵
www.biorxiv.org/content/10.6...
In our updated preprint with @v-hornung.bsky.social’s lab, we show that a single point mutation in this site abolishes the LPS response in macrophages 🧵
www.biorxiv.org/content/10.6...
Conserved catalytic activity of animal TIR domains functions in TLR4 signaling
The Toll/interleukin-1 receptor (TIR) domain is important for immune signaling across bacteria, plants, and animals. In animal innate immunity, TIR domains are thought to function as adaptors mediatin...
www.biorxiv.org
November 3, 2026 at 11:41 AM
The catalytic residue of the TLR4 TIR is required for immune signaling in human cells.
In our updated preprint with @v-hornung.bsky.social’s lab, we show that a single point mutation in this site abolishes the LPS response in macrophages 🧵
www.biorxiv.org/content/10.6...
In our updated preprint with @v-hornung.bsky.social’s lab, we show that a single point mutation in this site abolishes the LPS response in macrophages 🧵
www.biorxiv.org/content/10.6...
"The patient is enrolled in the CARE study (NCT04715191), a first-in-human, Phase 1 trial evaluating glypican-3-specific chimeric antigen receptor (GPC3-CAR) T cells armed with interleukin-15 and -21 (IL15 and IL21)." - Let's break this down!
November 4, 2026 at 2:25 PM
"The patient is enrolled in the CARE study (NCT04715191), a first-in-human, Phase 1 trial evaluating glypican-3-specific chimeric antigen receptor (GPC3-CAR) T cells armed with interleukin-15 and -21 (IL15 and IL21)." - Let's break this down!
Merck drops Sutro-partnered solid tumor cytokine candidate
Merck has discontinued MK-1484, an engineered interleukin-2 agonist developed alongside Sutro Biopharma that was in a Phase 1 trial as a monotherapy and alongside Keytruda.
via Fierce Biotech
#biotech
Merck has discontinued MK-1484, an engineered interleukin-2 agonist developed alongside Sutro Biopharma that was in a Phase 1 trial as a monotherapy and alongside Keytruda.
via Fierce Biotech
#biotech
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 6, 2026 at 10:10 PM
Merck drops Sutro-partnered solid tumor cytokine candidate
Merck has discontinued MK-1484, an engineered interleukin-2 agonist developed alongside Sutro Biopharma that was in a Phase 1 trial as a monotherapy and alongside Keytruda.
via Fierce Biotech
#biotech
Merck has discontinued MK-1484, an engineered interleukin-2 agonist developed alongside Sutro Biopharma that was in a Phase 1 trial as a monotherapy and alongside Keytruda.
via Fierce Biotech
#biotech
These cells were also "armored" with IL15 and IL21 (interleukin 15 and interleukin 21). These are signaling molecules normally produced by your body. In this case, they act synergistically to encourage the CAR T cells to multiply and persist - essentially an immune turbo boost for the therapy.
November 4, 2026 at 2:56 PM
These cells were also "armored" with IL15 and IL21 (interleukin 15 and interleukin 21). These are signaling molecules normally produced by your body. In this case, they act synergistically to encourage the CAR T cells to multiply and persist - essentially an immune turbo boost for the therapy.
From our Cell and Animal Models of #Gastrointestinal #Disease collection comes, Buprenorphine affects the initiation and severity of interleukin-induced #acute #pancreatitis in mice (Sarah Jahangir et al. @MayoClinic):
https://ow.ly/qPLW5104gOc
https://ow.ly/qPLW5104gOc
November 5, 2026 at 8:00 PM
From our Cell and Animal Models of #Gastrointestinal #Disease collection comes, Buprenorphine affects the initiation and severity of interleukin-induced #acute #pancreatitis in mice (Sarah Jahangir et al. @MayoClinic):
https://ow.ly/qPLW5104gOc
https://ow.ly/qPLW5104gOc
US Interleukin Market Size, Industry Growth, Trends, 2035 www.marketresearchfuture.com/reports/us-i...
US Interleukin Market Size, Industry Growth, Trends, 2035
US Interleukin Market share register 155.75 USD Million in 2024, projected to grow 5.62 % CAGR to reach USD Million 284.37 during the forecast period 2025 - 2035.
www.marketresearchfuture.com
November 2, 2026 at 8:05 AM
US Interleukin Market Size, Industry Growth, Trends, 2035 www.marketresearchfuture.com/reports/us-i...
Long COVID Reveals Hidden IL-1 Immune Disruption, Study Finds
www.thailandmedical.news/news/long-co...
www.thailandmedical.news/news/long-co...
Long COVID Reveals Hidden IL-1 Immune Disruption, Study Finds - Thailand Medical News
New research from Spain has uncovered an important disturbance in the immune system of people with Long COVID, highlighting abnormalities in the interleukin-1 (IL-1) inflammatory pathway even months after their initial coronavirus infection. However, scientists found no single blood biomarker capable of reliably distinguishing patients with persistent symptoms from those who recovered. Resear...
www.thailandmedical.news
November 4, 2026 at 2:51 AM
Long COVID Reveals Hidden IL-1 Immune Disruption, Study Finds
www.thailandmedical.news/news/long-co...
www.thailandmedical.news/news/long-co...
Cerebral white matter integrity in Type-2 Diabetes Mellitus and integrated role of Interleukin-6: Findings in multiethnic middle-aged and older US-adults #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2026.11.02.26367084v1
https://www.medrxiv.org/content/10.64898/2026.11.02.26367084v1
November 3, 2026 at 5:03 PM
Cerebral white matter integrity in Type-2 Diabetes Mellitus and integrated role of Interleukin-6: Findings in multiethnic middle-aged and older US-adults #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2026.11.02.26367084v1
https://www.medrxiv.org/content/10.64898/2026.11.02.26367084v1
COPD can be associated with exacerbations despite maintenance therapy. Two phase 2 trials tested add-on tozorakimab, a monoclonal antibody that inhibits interleukin-33 activity. Research findings from the phase 3 OBERON and TITANIA trials are summarized in a new video. https://nej.md/47Edhqp
October 31, 2026 at 6:00 PM
COPD can be associated with exacerbations despite maintenance therapy. Two phase 2 trials tested add-on tozorakimab, a monoclonal antibody that inhibits interleukin-33 activity. Research findings from the phase 3 OBERON and TITANIA trials are summarized in a new video. https://nej.md/47Edhqp
New experiments present a rational cytokine-engineering strategy to activate immune signaling networks and provide clues about whether the cytokine IL-39 is found in the human body—a longstanding debate in immunology.
See more in Science Signaling: scim.ag/4zhP8RX
See more in Science Signaling: scim.ag/4zhP8RX
Subunit engineering enables the generation of human interleukin-39 as a proinflammatory cytokine
Rational design enables human cells to produce an inflammatory cytokine that may not be made naturally.
scim.ag
November 4, 2026 at 4:23 PM
New experiments present a rational cytokine-engineering strategy to activate immune signaling networks and provide clues about whether the cytokine IL-39 is found in the human body—a longstanding debate in immunology.
See more in Science Signaling: scim.ag/4zhP8RX
See more in Science Signaling: scim.ag/4zhP8RX
New from our lab: Eosinophil activation is associated with cleavage of IL-5Rα to form soluble IL-5Rα - a biomarker for eosinophil activation and an inhibitor of IL-5 on eosinophils, suggesting it is a potential drug target for eosinophilic asthma.
academic.oup.com/ajrccm/advan...
academic.oup.com/ajrccm/advan...
Cleavage of Interleukin-5 receptor-α from eosinophils to a soluble form is linked to activation
Jian Luo, James Melhorn, Corrado Pelaia, Wei Luo, Isobel Turner, Jennifer Van Heerden, Sarah Barden, Luzheng Xue, Ian D Pavord, Timothy S C Hinks; Cleavage
academic.oup.com
November 4, 2026 at 9:33 PM
New from our lab: Eosinophil activation is associated with cleavage of IL-5Rα to form soluble IL-5Rα - a biomarker for eosinophil activation and an inhibitor of IL-5 on eosinophils, suggesting it is a potential drug target for eosinophilic asthma.
academic.oup.com/ajrccm/advan...
academic.oup.com/ajrccm/advan...